266 related articles for article (PubMed ID: 28511869)
21. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
22. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
[TBL] [Abstract][Full Text] [Related]
23. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.
Brasky TM; Felix AS; Cohn DE; McMeekin DS; Mutch DG; Creasman WT; Thaker PH; Walker JL; Moore RG; Lele SB; Guntupalli SR; Downs LS; Nagel CI; Boggess JF; Pearl ML; Ioffe OB; Park KJ; Ali S; Brinton LA
J Natl Cancer Inst; 2017 Mar; 109(3):1-10. PubMed ID: 28376204
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
25. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.
Maeda K; Tsuda H; Hashiguchi Y; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2002 Apr; 33(4):386-91. PubMed ID: 12055672
[TBL] [Abstract][Full Text] [Related]
26. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
27. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers.
Altman AD; Ferguson SE; Atenafu EG; Köbel M; McAlpine JN; Panzarella T; Lau S; Gien LT; Gilks B; Clarke B; Cameron A; Nelson G; Han G; Samouëlian V; Ho TC; Louie K; Bernardini MQ
Gynecol Oncol; 2015 Nov; 139(2):268-74. PubMed ID: 26352641
[TBL] [Abstract][Full Text] [Related]
28. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
29. Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma.
Yano M; Ito K; Yabuno A; Ogane N; Katoh T; Miyazawa M; Miyazawa M; Hasegawa K; Narahara H; Yasuda M
Mod Pathol; 2019 Jul; 32(7):1023-1031. PubMed ID: 30742011
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
Matsuo K; Machida H; Takiuchi T; Garcia-Sayre J; Yessaian AA; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):41-49. PubMed ID: 28215841
[TBL] [Abstract][Full Text] [Related]
31. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.
Fadare O; Gwin K; Desouki MM; Crispens MA; Jones HW; Khabele D; Liang SX; Zheng W; Mohammed K; Hecht JL; Parkash V
Mod Pathol; 2013 Aug; 26(8):1101-10. PubMed ID: 23524907
[TBL] [Abstract][Full Text] [Related]
32. MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas.
Eppich S; Kuhn C; Schmoeckel E; Mayr D; Mahner S; Jeschke U; Gallwas J; Heidegger HH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630554
[TBL] [Abstract][Full Text] [Related]
33. MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer.
Srdelić S; Kuzmić-Prusac I; Spagnoli GC; Juretić A; Čapkun V
Int J Gynecol Pathol; 2019 Jan; 38(1):59-65. PubMed ID: 29140883
[TBL] [Abstract][Full Text] [Related]
34. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
35. Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
Huvila J; Laajala TD; Edqvist PH; Mardinoglu A; Talve L; Pontén F; Grénman S; Carpén O; Aittokallio T; Auranen A
Gynecol Oncol; 2018 Apr; 149(1):173-180. PubMed ID: 29486992
[TBL] [Abstract][Full Text] [Related]
36. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
37. The up-regulation profiles of p21WAF1/CIP1 and RUNX1/AML1 correlate with myometrial infiltration in endometrioid endometrial carcinoma.
Planagumà J; Gonzalez M; Doll A; Monge M; Gil-Moreno A; Baró T; García A; Xercavins J; Alameda F; Abal M; Reventós J
Hum Pathol; 2006 Aug; 37(8):1050-7. PubMed ID: 16867868
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
39. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
40. A proposed model for endometrial serous carcinogenesis.
Zheng W; Xiang L; Fadare O; Kong B
Am J Surg Pathol; 2011 Jan; 35(1):e1-e14. PubMed ID: 21164282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
